Research
Hormonal
Mycoprotein consumption reduces postprandial insulin response and energy intake at high doses (132g) compared to chicken, without altering glycemic response.
If you are overweight or obese, incorporating mycoprotein into your meals, particularly in larger portions (around 132g of protein), may help reduce your insulin response and naturally lower your calorie intake at the next meal compared to chicken.
ModerateSupportsMEDIUM confidence
Results indicated that mycoprotein meals had no effect on glycemic response, but they elicited a reduced insulin response at every level compared with chicken. Energy intake at an ad libitum lunch following test meals was lower only at the highest level of mycoprotein (25).
Why this rating
Based on a randomized trial cited in the review.
Source
Mycoprotein: The Future of Nutritious Nonmeat Protein, a Symposium Review
Tim J. A. Finnigan et al. · Current Developments in Nutrition · 2019
DOI 10.1093/cdn/nzz021
narrative_reviewCited 234×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The incidence of allergic reactions to mycoprotein is exceptionally low (1 in 9 million packages) compared to common allergens, making it a safe novel protein source.Good
- Consuming mycoprotein provides a sustained release of essential amino acids (EAAs) and branched-chain amino acids (BCAAs) compared to milk protein, supporting muscle protein synthesis without rapid spikes.Moderate
- Mycoprotein consumption is associated with a significant reduction in plasma cholesterol, particularly in smaller lipoprotein particles, likely due to its high fiber content (chitin and beta-glucans).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →